@article{mbs:/content/journal/micro/10.1099/mic.0.2008/017434-0, author = "Bhowruth, Veemal and Brown, Alistair K. and Besra, Gurdyal S.", title = "Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636", journal= "Microbiology", year = "2008", volume = "154", number = "7", pages = "1866-1875", doi = "https://doi.org/10.1099/mic.0.2008/017434-0", url = "https://www.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.2008/017434-0", publisher = "Microbiology Society", issn = "1465-2080", type = "Journal Article", keywords = "MTBE, methyl tert-butyl ether", keywords = "NaOMe, sodium methoxide", keywords = "FAMEs/MAMEs, fatty/mycolic acid methyl esters", keywords = "FAS, fatty acid synthase", keywords = "ACP, acyl carrier protein", keywords = "MeOH, methanol", keywords = "TB, tuberculosis", abstract = "The identification of potential new anti-tubercular chemotherapeutics is paramount due to the recent emergence of extensively drug-resistant strains of Mycobacterium tuberculosis (XDR-TB). Libraries of NAS-21 and NAS-91 analogues were synthesized and evaluated for their whole-cell activity against Mycobacterium bovis BCG. NAS-21 analogues 1 and 2 demonstrated enhanced whole-cell activity in comparison to the parental compound, and an M. bovis BCG strain overexpressing the dehydratase enzyme Rv0636 was resistant to these analogues. NAS-91 analogues with ortho-modifications gave enhanced whole-cell activity. However, extension with biphenyl modifications compromised the whole-cell activities of both NAS-21 and NAS-91 analogues. Interestingly, both libraries demonstrated in vitro activity against fatty acid synthase II (FAS-II) but not FAS-I in cell-free extracts. In in vitro assays of FAS-II inhibition, NAS-21 analogues 4 and 5 had IC50 values of 28 and 19 μg ml−1, respectively, for the control M. bovis strain, and the M. bovis BCG strain overexpressing Rv0636 showed a marked increase in resistance. In contrast, NAS-91 analogues demonstrated moderate in vitro activity, although increased resistance was again observed in FAS-II activity assays with the Rv0636-overexpressing strain. Fatty acid methyl ester (FAME) and mycolic acid methyl ester (MAME) analysis of M. bovis BCG and the Rv0636-overexpressing strain revealed that the effect of the drug was relieved in the overexpressing strain, further implicating and potentially identifying Rv0636 as the target for these known FabZ dehydratase inhibitors. This study has identified candidates for further development as drug therapeutics against the mycobacterial FAS-II dehydratase enzyme.", }